Dr Tia Higano provides her perspective on ERA 223: A phase 3 trial of Ra-223 in combination with AAP in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant mCRPC


An update on the treatment of patients with mCRPC with RA-223 plus AAP

Dr Tia Higano comments on the results of ERA223, a phase 3 trial that evaluated concurrent treatment of radium-223 (Ra-223) and abiraterone acetate and prednisone/prednisolone (AAP). Ra-223 and AAP are tested in the treatment of asymptomatic or mildly symptomatic chemotherapy naïve patients with bone predominant metastatic castration-resistant prostate cancer (mCRPC).

Dr Higano highlights important findings that influence clinical practice. In the accompanying slide set Dr Higano presents ERA223 trial results on the primary endpoint of symptomatic skeletal event-free survival, and the secondary endpoint of overall survival. Data on frequency of fractures is examined and the effect of bone health agents. Dr Higano concludes with advice on the use of radium and bone health agents in mCRPC. The video and accompanying slides provide medical education for medical oncologists, and we hope you find it of use for your own clinical practice.

Dr Higano is an Adjunct Professor in the Department of Urologic Science at the University of British Columbia, and serves as the Medical Director of the Prostate Cancer Supportive Care Program (pcscprogram.ca). She graduated from University of Massachusetts Medical School, finished internal medicine residency at Mayo Graduate School of Medicine, and completed hematology/oncology fellowship at University of Washington and Fred Hutchinson. Her research interests focus on new drug development including immunotherapy, the effects of androgen deprivation therapy on the male body and mind, and development of supportive care/survivorship programs for prostate cancer patients and their partners.

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Medical Grants from Bayer, AstraZeneca and Eisai Europe Limited.

Meet the experts

Other programmes of interest

Breast-Cancer-Connect-ER-HER2-low-thumbnail-BR2310 Tweetorial
Oncology 
Tweetorial video: Treating ER+/HER2-low metastatic breast cancer, 2L and beyond

Journey through a patient case from testing and diagnosis to treatment and AE management

Experts
Dr Aditya Bardia
Endorsed by
GRASP
  • clock 11 MIN
  • calendar Apr 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.
NSCLC-perseverance-pays-off- thumbnail-PO2305 Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
Podcast
Oncology 
mCRC: Optimising patient outcomes with late-line treatment

Maximising outcomes for patients with advanced CRC

Experts
Assoc. Prof. Gerald Prager, Dr Victor Hugo Fonseca de Jesus
Endorsed by
Digestive Cancers Europe 5th anniversary
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
Lung cancer expert panel Conference update
Oncology 
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.